From Phase 1 Screening to Commercial Strategy

As increasingly complex, poorly water-soluble molecules enter development, choosing an amorphous solid dispersion (ASD) technology based only on near-term needs can create costly challenges later. This overview examines why leading approaches, including spray drying, hot-melt extrusion, co-precipitation, and KinetiSol™, should be evaluated early and on a drug-specific basis. Through comprehensive screening, optimization, biopharmaceutical analysis, and early manufacturing assessment, developers can identify the right formulation and process before late-stage commitments are made, reducing the risk of reformulation, clinical delays, PK bridging studies, manufacturing constraints, and rising cost of goods. With all major ASD technologies under one roof, AustinPx helps clients protect scalability, patient experience, and long-term asset value.